<p>Baseline and endline outcomes among HIV-positive pregnant and postpartum women in Tanzania, stratified by treatment group, 2014–2015<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0181919#t002fn003" target="_blank"><sup>a</sup></a>.</p
OBJECTIVE: To examine the association between maternal HIV infection and pregnancy outcomes controll...
BACKGROUND: Maternal morbidity and mortality among HIV-infected women is a global concern. This stud...
Purpose The Hlabisa pregnancy cohort was established to evaluate the effectiveness of prevention of ...
Background: A human immunodeficiency virus (HIV) infection in pregnant women is an important medical...
BackgroundIMPAACT PROMISE 1077BF/FF was a randomized study of antiretroviral therapy (ART) strategie...
In 2015, the majority (80%) of the 1.2 million HIV-positive pregnant women globally, most of whom re...
Objective To compare health outcomes following initiation of antiretroviral therapy (ART) for asympt...
Objective: To examine time trends in antenatal factors and delivery characteristics in Northern Tanz...
Globally, 1.4 million HIV-positive women become pregnant annually, of whom 92% reside in sub-Saharan...
BackgroundThe Option B+ strategy streamlines delivery of HIV antiretroviral therapy (ART) to pregnan...
OBJECTIVE:To examine time trends in antenatal factors and delivery characteristics in Northern Tanza...
Highly active antiretroviral treatment (HAART) has only been recently recommended for HIV-infected p...
<p>Secondary study outcomes evaluating a combination HIV prevention intervention amongst pregnant an...
BACKGROUND: HIV infection is a major contributor to maternal mortality in resource-limited settings....
Background: HIV infection in pregnant women is delicate both for the mother and her child. With the ...
OBJECTIVE: To examine the association between maternal HIV infection and pregnancy outcomes controll...
BACKGROUND: Maternal morbidity and mortality among HIV-infected women is a global concern. This stud...
Purpose The Hlabisa pregnancy cohort was established to evaluate the effectiveness of prevention of ...
Background: A human immunodeficiency virus (HIV) infection in pregnant women is an important medical...
BackgroundIMPAACT PROMISE 1077BF/FF was a randomized study of antiretroviral therapy (ART) strategie...
In 2015, the majority (80%) of the 1.2 million HIV-positive pregnant women globally, most of whom re...
Objective To compare health outcomes following initiation of antiretroviral therapy (ART) for asympt...
Objective: To examine time trends in antenatal factors and delivery characteristics in Northern Tanz...
Globally, 1.4 million HIV-positive women become pregnant annually, of whom 92% reside in sub-Saharan...
BackgroundThe Option B+ strategy streamlines delivery of HIV antiretroviral therapy (ART) to pregnan...
OBJECTIVE:To examine time trends in antenatal factors and delivery characteristics in Northern Tanza...
Highly active antiretroviral treatment (HAART) has only been recently recommended for HIV-infected p...
<p>Secondary study outcomes evaluating a combination HIV prevention intervention amongst pregnant an...
BACKGROUND: HIV infection is a major contributor to maternal mortality in resource-limited settings....
Background: HIV infection in pregnant women is delicate both for the mother and her child. With the ...
OBJECTIVE: To examine the association between maternal HIV infection and pregnancy outcomes controll...
BACKGROUND: Maternal morbidity and mortality among HIV-infected women is a global concern. This stud...
Purpose The Hlabisa pregnancy cohort was established to evaluate the effectiveness of prevention of ...